Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | CLK3 | P49761 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21611042 | 0.95 | DYRK1A (0.53) | TTKDYRK1ADYRK3CSNK1ECLK1 | |
| SCHEMBL21738228 | 0.93 | TTK (0.52) | TTKDYRK1ADYRK3CSNK1ECLK1 | |
| SCHEMBL21611065 | 0.92 | TTK (0.56) | TTKDYRK1ADYRK3CSNK1ECLK1 | |
| SCHEMBL21661690 | 0.89 | DYRK1A (0.56) | TTKDYRK1ADYRK3CSNK1ECLK1 | |
| SCHEMBL21638145 | 0.89 | DYRK1A (0.67) | TTKDYRK1ADYRK3CSNK1ECLK1 | |
| SCHEMBL21738218 | 0.88 | TTK (0.56) | TTKDYRK1ADYRK3CSNK1ECLK1 | |
| SCHEMBL21611049 | 0.87 | TTK (0.53) | TTKDYRK1ADYRK3CSNK1ECLK1 | |
| SCHEMBL21738262 | 0.87 | TTK (0.56) | TTKDYRK1ADYRK3CSNK1ECLK1 | |
| SCHEMBL21609963 | 0.86 | TTK (0.52) | TTKDYRK1ADYRK3CSNK1ECLK1 | |
| SCHEMBL21611008 | 0.85 | TTK (0.55) | TTKDYRK1ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117892-B2 | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION | 2021-09-14 | — | — | US | disclosed |
| US-20200207756-A1 | PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-07-02 | — | — | US | disclosed |
| WO-2018174650-A9 | PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES | 재단법인 대구경북첨단의료산업진흥재단 | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117892-B2 | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases | DYRK1A, DYRK2, DYRK1B | TTK 100/4885DYRK1A 1/4885DYRK3 4/4885 |
| US-20200207756-A1 | PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES | DYRK1A, DYRK2, DYRK4 | TTK 93/4885DYRK1A 1/4885DYRK3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.